Development of nanobioconjugate to treat HER2eu expressing breast tumors

摘要

Invasive breast cancer is the most frequentmalignancy diagnosed in women in the UnitedStates. Nearly 25 25-30% patients overexpressingHER2/ neu oncoprotein suffer of a moreaggressive disease. HER2/ neu targetingtherapies have shown significant protection ofpatients, however they deve develop resistance to thislop therapy and eventually die. We have engineereda new nanoplatform based on poly(malic acid)(PMLA) called Polycefin, for specific tumorbiomarker targeting and modulation of theimmune system at the same time. Our in vivotreatment r results suggest that Polycefinesults nanobiopolymer is a promising drug for thetreatment of HER2/ neu expressing tumors.